7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-6-(2-cyclopropylethynyl)-7-[(3R,5S)-5-methyl-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]-N-[(1R)-1-phenylethyl]-, (2E)-2-butenedioate (1:1)

TAS2940 fumarate (3.1-25 mg/kg; po; once daily; for 14days) inhibits tumor growth in xenograft mouse models with ERBB aberrations: HER2 amplification, HER2/EGFR exon 20 insertions, and EGFR vIII mutation^[1].
PK parameters of TAS2940 after a single oral administration or multiple oral administrations for 7 days in male BALB/cAJcl-nu/nu mice^[1].